Navamedic ASA
OSE:NAVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (18.4), the stock would be worth kr10.73 (50% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 37 | kr21.6 |
0%
|
| 3-Year Average | 18.4 | kr10.73 |
-50%
|
| 5-Year Average | 19.8 | kr11.54 |
-47%
|
| Industry Average | 308.5 | kr180.26 |
+735%
|
| Country Average | 13.4 | kr7.85 |
-64%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
kr554m
|
/ |
Jan 2026
kr16.3m
|
= |
|
|
kr554m
|
/ |
Dec 2026
kr12.2m
|
= |
|
|
kr554m
|
/ |
Dec 2027
kr40.8m
|
= |
|
|
kr554m
|
/ |
Dec 2028
kr67.3m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| NO |
N
|
Navamedic ASA
OSE:NAVA
|
518m NOK | 37 | -22.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD | 30.4 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD | 21.2 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 12.9 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 22.5 | 28.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 15.9 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD | 11.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.4 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 10.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 8.8 | 16.8 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 3.6 |
| Median | 13.4 |
| 70th Percentile | 22.2 |
| Max | 40 612.5 |
Other Multiples
Navamedic ASA
Glance View
Navamedic ASA engages in the delivery and marketing of pharmaceutical products to patients, hospitals, and pharmacies. The company is headquartered in Oslo, Oslo. The company went IPO on 2006-03-31. The firm in-licenses, acquires and markets pharmaceuticals and other healthcare products in northern Europe. The product portfolio includes original and generic pharmaceuticals, as well as food supplements, medical devices and other healthcare products. Navamedic ASA has three subsidiaries: Observe Medical, a Swedish medical technology company; Vitaflo Scandinavia AB, which focuses on in-licensing and buying pharmaceuticals and other healthcare products within a few selected knowledge areas; and Navamedic ehf, which builds its business around the sales and marketing of generic pharmaceuticals targeted towards the Nordic and BeNeLux markets. The Navamedic business unit is built upon the cooperation with the South African pharmaceutical company Aspen Healthcare. The Company’s largest shareholder is Nobelsystem Scandinavia.
